| Literature DB >> 35626781 |
Sonja Diez1, Lea Emilia Bell1, Julia Moosmann2, Christel Weiss3, Hanna Müller4, Manuel Besendörfer1.
Abstract
Necrotizing enterocolitis (NEC) continues to cause high morbidity and mortality. Identifying early predictors for severe NEC is essential to improve therapy and optimize timing for surgical intervention. We present a retrospective study of patients with NEC, treated between 2010 and 2020, trying to identify factors influencing the severity of NEC. Within the study period, 88 affected infants with NEC or NEC-like symptoms are analyzed. A multiple logistic regression analysis reveals the following three independent predictors for NEC in Bell stage III: red blood cell transfusion (p = 0.027 with odds ratio (OR) = 3.298), sonographic findings (p = 0.037; OR = 6.496 for patients with positive vs. patients without pathological findings) and cardiac anatomy (p = 0.015; OR = 1.922 for patients with patent ductus arteriosus (PDA) vs. patients with congenital heart disease (CHD); OR = 5.478/OR = 2.850 for patients with CHD/PDA vs. patients without cardiac disease). Results are summarized in a clinical score for daily application in clinical routine. The score is easy to apply and combines clinically established parameters, helping to determine the timing of surgical intervention.Entities:
Keywords: Bell stage; NEC; clinical score; congenital heart disease; fulminant NEC; necrotizing enterocolitis
Year: 2022 PMID: 35626781 PMCID: PMC9139239 DOI: 10.3390/children9050604
Source DB: PubMed Journal: Children (Basel) ISSN: 2227-9067
Figure 1Flow diagram of the selection process of the study’s population.
Basic demographic and clinical data. Summary of patients’ characteristics.
| Parameter | Study Population |
|---|---|
| Sex (n (%)) | |
| Male | 57 (65%) |
| Female | 31 (35%) |
| Umbilical cord pH (median (range)) | 7.3 (6.7–7.5) |
| Gestational age at birth (weeks; median (range)) | 33.1 (23.0–41.6) |
| Weight at birth (g; median (range)) | 1745 (490–4120) |
| Ventilation before NEC (n (%)) | |
| Intubation/ventilation | 61 (69%) |
| CPAP | 12 (14%) |
| None | 15 (17%) |
| First hit (pre- and perinatal inflammatory and/or hypoxic stimuli) (n (%)) | |
| Yes | 10 (11%) |
| No | 78 (89%) |
| Maternal risk factors (chorioamnionitis, preeclampsia) (n (%)) | |
| Yes | 4 (4%) |
| No | 84 (96%) |
| Cardiac status (n (%)) | |
| CHD | 29 (33%) |
| PDA | 12 (14%) |
| No cardiac malformation | 47 (53%) |
| Surgical treatment of cardiac malformation (CHD, PDA) before NEC (n (%)) | |
| Yes | 31 (35%) |
| No | 57 (65%) |
| Prostaglandin application (n (%)) | |
| Yes | 21 (24%) |
| No | 67 (76%) |
| Application of COX-2-inhibitors (n (%)) | |
| Yes | 14 (16%) |
| No | 74 (84%) |
| Transfusion of red blood cells (n (%)) | |
| Yes | 37 (42%) |
| No | 51 (58%) |
| Transfusion of fresh frozen plasma (n (%)) | |
| Yes | 33 (38%) |
| No | 55 (62%) |
| Transfusion of platelets (n (%)) | |
| Yes | 23 (26%) |
| No | 65 (74%) |
| Application of inotropes (n (%)) | |
| Yes | 38 (43%) |
| No | 50 (57%) |
| Nutrition before diagnosis (n (%)) | |
| None | 15 (17%) |
| Human milk | 9 (10%) |
| Formula | 19 (22%) |
| Both | 45 (51%) |
| Age at NEC diagnosis (days; median (range)) | 13.0 (0–94) |
| Bell stage (n (%)) | |
| Ia | 9 (10%) |
| Ib | 13 (15%) |
| IIa | 19 (22%) |
| IIb | 16 (18%) |
| IIIa | 4 (4%) |
| IIIb | 27 (31%) |
| Treatment of NEC (n (%)) | |
| Surgery | 40 (45%) |
| Conservative treatment | 48 (55%) |
| Number of needed surgeries (n (%)) | n = 40 |
| 1 | 28 (70%) |
| 2 or more | 12 (30%) |
| Proof of intraoperative intraperitoneal bacteria (n (%)) | n = 40 |
| Yes | 18 (45%) |
| No | 22 (55%) |
| Macroscopic intestinal necrosis (n (%)) | n = 40 |
| Yes | 31 (78%) |
| No | 9 (22%) |
| Macroscopic intestinal perforation (n (%)) | n = 40 |
| Yes | 27 (67%) |
| No | 13 (33%) |
| Short bowel syndrome (n (%)) | |
| Yes | 8 (9%) |
| No | 80 (91%) |
| Outcome (n (%)) | |
| Survival | 80 (91%) |
| Death | 8 (9%) |
| C-reactive protein at diagnosis (mg/L; median (range)) | 7.0 (0–288.7) |
| Neutrophil-to-lymphocyte-ratio at diagnosis (median (range)) | 1.7 (0.11–42.11) |
| Monocyte-to-lymphocyte-ratio at diagnosis (median (range)) | 0.3 (0–4.95) |
| Thrombocyte-to-lymphocyte-ratio at diagnosis (median (range)) | 121.6 (8.5–1275) |
| Maximum C-reactive protein (mg/L; median (range)) | 40.9 (0–325.2) |
| Maximum neutrophil-to-lymphocyte-ratio (median (range)) | 1.6 (0.11–42.11) |
| Maximum monocyte-to-lymphocyte-ratio (median (range)) | 0.3 (0–4.95) |
| Maximum thrombocyte-to-lymphocyte-ratio (median (range)) | 89.5 (19.7–1580) |
Abbreviations: NEC: necrotizing enterocolitis; PDA: patent ductus arteriosus; CHD: congenital heart defect.
Clinical parameters of patients with Bell stage III in comparison to patients with NEC in Bell stage I–II. Significant findings were highlighted.
| Bell Stage I–II | Bell Stage III | Test | ||
|---|---|---|---|---|
| Umbilical cord pH (median (range)) | 7.3 (7.0–7.5) | 7.3 (6.7–7.4) | 0.4360 | U test |
| Gestational age at birth (weeks; median (range)) | 33.4 (23.0–41.6) | 32.7 (23.6–39.6) | 0.9886 | U test |
| Weight at birth (g; median (range)) | 1680 (530–4120) | 1870 (490–3680) | 0.9289 | U test |
| Ventilation before NEC (n (%)) | 0.0039 * | Chi2 | ||
| Intubation/Ventilation | 33 (58%) | 28 (90%) | ||
| CPAP | 12 (21%) | 0 | ||
| None | 12 (21%) | 3 (10%) | ||
| First hit (pre- and perinatal inflammatory and/or hypoxic stimuli) (n (%)) | 0.7367 | Fisher | ||
| Yes | 6 (11%) | 4 (13%) | ||
| No | 51 (89%) | 27 (87%) | ||
| Cardiac status (n (%)) | 0.0135 ** | Chi2 | ||
| CHD | 14 (25%) | 15 (49%) | ||
| PDA | 6 (10%) | 6 (19%) | ||
| No cardiac malformation | 37 (65%) | 10 (32%) | ||
| Application of catecholamines (n (%)) | 0.0114 | Chi2 | ||
| Yes | 19 (33%) | 19 (61%) | ||
| No | 38 (67%) | 12 (39%) | ||
| Nutrition before diagnosis (n (%)) | 0.2661 | Chi2 | ||
| None | 7 (12%) | 8 (26%) | ||
| Human milk | 5 (9%) | 4 (13%) | ||
| Formula | 12 (21%) | 7 (22%) | ||
| Both | 33 (58%) | 12 (39%) | ||
| Age at diagnosis (days; median (range)) | 10.0 (0–49) | 20.0 (0–94) | 0.2112 | U test |
| Positive findings on abdominal ultrasound (n (%)) | 0.0455 | Chi2 | ||
| Yes | 41 (75%) | 29 (93%) | ||
| No | 16 (25%) | 2 (7%) | ||
| Intraoperative proof of intraperitoneal bacteria (n (%)) | n = 10 | n = 30 | 0.4645 | Fisher |
| Yes | 3 (30%) | 15 (50%) | ||
| No | 7 (70%) | 15 (50%) | ||
| Macroscopic intestinal perforation (n (%)) | n = 10 | n = 30 | <0.0001 | Fisher |
| Yes | 1 (10%) | 26 (87%) | ||
| No | 9 (90%) | 4 (13%) | ||
| Maximum C-reactive protein (mg/L; median (range)) | 7.5 (0–259.6) | 167.2 (1.5–325.2) | <0.0001 | U test |
Abbreviations: NEC: necrotizing enterocolitis; PDA: patent ductus arteriosus; CHD: congenital heart defect. * Intubation vs. CPAP: p = 0.0069; intubation vs. none: p = 0.2022; CPAP vs. none: p = 0.6924. ** CHD vs. PDA: p = 1; CHD vs. no cardiac malformation: p = 0.0183; PDA vs. no cardiac malformation: p = 0.2061.
Figure 2Pneumatosis intestinalis and/or hepatis. Illustrated are patients in Bell stage II and III, diagnosed with intramural or portal venous gas on ultrasound and X-ray.
Figure 3Bell stage III score. Independent predictors for NEC in Bell stage III according to the presented equation summarized in a score for clinical application. Presence of each factor increases risk for high Bell stage 2.4-fold.
Exclusion of confounding parameters. Cardiac status was not a substantially influencing variable of the score, as shown with comparable delta in both subgroups.
| Pathological Findings in Ultrasound Diagnosis | RBC Transfusion | |||||
|---|---|---|---|---|---|---|
| Bell Stage I–II | Bell Stage III | Delta | Bell Stage I–II | Bell Stage III | Delta | |
| CHD | 64% | 87% | 23% | 36% | 60% | 24% |
| PT/PDA | 78% | 100% | 25% | 30% | 63% | 23% |
Abbreviations: CHD: congenital heart defect; PT: preterm infants; PDA: patent ductus arteriosus.